-
VEGF-A VEGFR-2 Signaling: Decoding the Blueprint of Angiogenesis for Therapeutic Insights(Post)
The orchestration of angiogenesis, the process by which new blood vessels form from pre-existing ones, is a complex symphony regulated by various molecular players. At the forefront of this int
Mast Cells IgE and Type 2 Immunity(Page) Complement: The Brake Matters More Than the Trigger(Post)Complement is firing on your own cells right now. Not in response to anything — C3 hydrolyses spontaneously in plasma at a low, constant rate, and every hydrolysed molecule is a potential convertase
CD8+ T Cells: Understanding the Role of Cytotoxic T Cells in Immunity(Post)Immunology · T LymphocytesCD8+ T Cells: Cytotoxic Mechanisms, Memory and ExhaustionCD8+ T cells kill infected and transformed cells directly, and they do it with a specificity nothing else in the immu
Antibody-Drug Conjugates: Internalisation, Trafficking & the Bystander Effect(Page) VEGF: Inflammation and Tumourigenesis(Post)What is VEGF? Vascular Endothelial Growth Factors (VEGFs) are a group of homodimeric polypeptides, and are master regulators of vascular development, maintenance and a
Vopratelimab: Unlocking the Potential of ICOS in Cancer Research(Post)What You Need to Know About VopratelimabWhat is Vopratelimab?Vopratelimab is an experimental monoclonal antibody that targets the Inducible T-cell CO-Stimulator (ICOS) protein, playing a
Atezolizumab: Unveiling the Role of Anti-PD-L1 in Cancer Research(Post)Quick Facts About AtezolizumabWhat is Atezolizumab?Atezolizumab is an anti-PD-L1 monoclonal antibody used in immunotherapy to treat various cancers by enhancing the immune system's abili
The PD-1 Pathway and Cancer Immunotherapy(Post)The initial identification of PD-1 as a potential target for cancer treatment occurred in the late 1990s and early 2000s through studies exploring the regulation of T-cell responses.
SIRPα Inhibition: Clearing Tumors by Promoting Phagocytosis(Post)Cancer cells are adept at avoiding destruction by the immune system, often exploiting specific pathways to escape detection and elimination. One of these key mechanisms involves the SIRPα
NF-κB Signalling Pathway: Canonical and Non-Canonical Routes(Post)NF-κB is not one pathway, it is two clocks running at different speeds. The canonical arm fires within minutes of TNF-α, IL-1β or LPS reaching the surface, peaks, and is switched off by feedback it e
Fletikumab: Unlocking the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About FletikumabWhat is Fletikumab?Fletikumab is an investigational monoclonal antibody targeting CD47, a key immune checkpoint that enables cancer cells to evade immune dest
Xeroderma pigmentosum: Causes, Inheritance, Treatment and Diagnosis(Post)What is Xeroderma Pigmentosum? Xeroderma pigmentosum (XP) also known De Sanctis-Cacchione syndrome is a rare genetic disorder that affects the skin, eyes and central nervous system. It is ca
Biomarkers in sepsis: Their Role in Early Detection and Management (Post)Sepsis, a life-threatening condition, is characterized by a dysregulated immune
Enfortumab Vedotin: Unveiling Its Role in Cancer Treatment and the Rise of Biosimilars(Post)Quick Facts About EnfortumabWhat is Enfortumab Vedotin?Enfortumab vedotin is an innovative cancer therapy, primarily used in treating urothelial carcinoma (bladder cancer) that has not r
Your Agonist Antibody Is Not an Agonist(Post)An agonist antibody does not activate its receptor. It gets held still by something else, and the receptors underneath cluster because they are crowded. That sentence sounds like a technicality and i
Th17 Cells and the IL-23 Axis(Page) Cytokine neutralisation network(Page) Ulviprubart: A Breakthrough in Autoimmune Disease Treatment(Post)Quick Facts About UlviprubartWhat is Ulviprubart?Ulviprubart is an experimental complement inhibitor designed to modulate immune responses in autoimmune diseases.What is the mechanism of
Unlocking the Potential of Anti-CD47 in Cancer Immunotherapy(Post)Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macropha